Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
KD5040
- Development stage
- Preclinical
- Lead developer
- Kyung Hee University
- Administration
- Oral
01
Overview
**KD5040** is an experimental modified Korean herbal medicine formula developed for Parkinson's disease research. It is prepared as a 3:1:1 mixture of Chunggantang, *Eugenia caryophyllata* and *Pogostemon cablin*. In MPTP-induced mouse models of Parkinson's disease, KD5040 showed neuroprotective and motor-function benefits; co-administration with levodopa improved motor outcomes at lower levodopa doses and reduced levodopa-induced dyskinesia measures. These findings are preclinical and do not establish clinical efficacy in people. ([pmc.ncbi.nlm.nih.gov](https://pmc.ncbi.nlm.nih.gov/articles/PMC6907061/))
- Other names
- modified Chunggan formulamodified Chunggantang
02
Targets
PPP1R1B (Protein phosphatase 1 regulatory inhibitor subunit 1B)
Beyond the preview
Go deeper on KD5040.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on KD5040.